NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

COLON DISEASE ORIENTED WORKING GROUP

AGENDA

OPEN SESSION

Venue: Delta Chelsea Hotel Date: Saturday, April 28th, 2007

Time: 8:00 am

Chairs: Dr. Derek Jonker & Dr. Sharlene Gill

8:00 am	WELCOME AND INTRODUCTION	Dr. D. Jonker/ Dr. S. Gill
8:05 am	UPDATE OF CLOSED TRIALS CO.17: A Phase III Randomized Multicenter Study of Cetuximab and Best Supportive Care vs. Best Supportive Care in patients with pretreated, metastatic, EGFR-positive colorectal carcinoma	Dr. D. Jonker
8:10am	UPDATE OF ACTIVE TRIALS CRC.2 (N0147): A Randomized Phase III Trial of Oxaliplatin Plus 5-FU with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer	Dr. S. Gill

CRC.3 (E5202): A Randomized Phase III Study Comparing 5FU Leucovorin and Oxaliplatin versus 5FU Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

IND.171: Phase I Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination with Standard Chemotherapy in Patients with Advanced Incurable NSCLC or CRC

8:20am INTERGROUP UPDATE

Dr. D. Jonker

NSABP C09: A Phase III Trial Comparing Oxaliplatin and Capecitabine and Hepatic Arterial Infusion of Floxuridine to Intravenous Oxaliplatin and Capecitabine in Patients with Resected or Ablated Metastasis to the Liver from CRC

CALGB 80405: A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5FU / Leucovorin with Bevacizumab, or Cetuximab, or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

SWOG S0600 iBET (Intergroup Bevacizumab Continuation Trial):

Dr. S. Berry

FOLFIRI/irinotecan plus cetuximab versus FOLFIRIR/irinotecan plus cetuximab and bevacizumab in patient with MCRC who have failed first-line oxaliplatin plus bevacizumab.

8:40 am UPDATE OF TRIALS IN DEVELOPMENT

CO.18: A Phase II Study of AZD2171 and Capecitabine versus Capecitabine Alone Dr. C. Cripps as 1st Line therapy in Patients with Metastatic Colorectal Cancer

CO.20: A Phase III Randomized Study of BMS582664 and Cetuximab versus Dr. L. Siu Cetuximab in Patients with Pretreated Metastatic CRC

9:00 am **New Trial Proposals**

The impact of physical activity on disease-free survival in patients with early Dr. C. Booth stage CRC: a randomized controlled trial

Phase II Irinotecan/Xeloda/Oxaliplatin (IXO) +/- Bevacizumab Dr. J. Maroun

9:45 am **CLOSING REMARKS & ADJOURNMENT** Dr. D. Jonker/ Dr. S. Gill